Login to Your Account



Genentech Reports Positive Phase II Vismodegib Results

By Tom Wall


Tuesday, June 21, 2011
A pivotal Phase II study of oral medicine vismodegib (RG3616/GDC-0449) showed positive results in people with inoperable, advanced basal cell carcinoma (BCC), a rare form of skin cancer, reported Genentech Inc., of South San Francisco, a member of the Roche Group.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription